Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size
862 studies found for:    "Mantle cell lymphoma"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
21 Withdrawn Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma
Conditions: Mantle Cell Lymphoma;   Lymphoma
Intervention: Procedure: PET/CT Scanning
22 Completed
Has Results 		Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: modified Hyper-CVAD
23 Active, not recruiting Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Rituximab;   Drug: Bortezomib;   Drug: Lenalidomide
24 Active, not recruiting An Open-label, Phase 2 Study of ACP 196 in Subjects With Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma (MCL)
Intervention: Drug: ACP-196
25 Recruiting Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)
Condition: Mantle Cell Lymphoma
Interventions: Drug: Rituximab;   Drug: bortezomib;   Drug: Cladribine
26 Not yet recruiting Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: Bortezomib, Cytarabine, Dexamethasone, Pegfilgrastim
27 Completed Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Iodine-131 Anti-B1 Antibody;   Drug: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)
28 Completed Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Procedure: Intensive Induction-BMT
29 Recruiting Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Ibrutinib;   Drug: bortezomib
30 Completed
Has Results 		Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Bortezomib;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone
31 Active, not recruiting Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma
Conditions: Mantle Cell Lymphoma;   Lymphoma
Interventions: Drug: Bortezomib;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Doxorubicin
32 Completed Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: bendamustine hydrochloride
33 Terminated
Has Results 		A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: P276-00
34 Completed Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Condition: MANTLE CELL LYMPHOMA
Intervention: Drug: Lenalidomide and Dexametasone
35 Active, not recruiting Phase II Study of Age‐Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: Rituximab, Bendamustine, Cytarabine.
36 Completed VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma
Conditions: Non-hodgkin's Lymphoma;   Mantle Cell Lymphoma
Interventions: Drug: Bortezomib;   Drug: BEAM;   Procedure: autologous peripheral blood stem cell transplantation
37 Terminated Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat
38 Completed Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)
Condition: Mantle Cell Lymphoma
Intervention: Drug: Y-90 Ibritumomab tiuxetan
39 Active, not recruiting Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma
Conditions: Follicular Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: Temsirolimus, Rituximab, Bendamustin
40 Recruiting A Study of ACP-196 in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma (MCL)
Intervention: Drug: ACP-196 in combination with BR
To Top

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
† Indicates status has not been verified in more than two years